- Home
- PSF vs DERM Comparison
PSF vs DERM Comparison
Compare PSF & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | DERM |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 210.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSF | DERM |
|---|---|---|
| Price | $20.50 | $8.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 25.0K | ★ 128.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,399,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | N/A | $55.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.82 |
| 52 Week Low | $16.00 | $3.54 |
| 52 Week High | $20.19 | $9.40 |
Technical Indicators
Market Signals| Indicator | PSF | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 58.86 | 53.99 |
| Support Level | $20.33 | $7.15 |
| Resistance Level | $20.49 | $8.40 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 90.00 | 72.03 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.